Cannabidiol in Medicine: A Review of its Therapeutic Potential in CNS Disorders

被引：138

作者：

Scuderi, Caterina ^{[1
]}

De Filippis, Daniele ^{[2
]}

Iuvone, Teresa ^{[2
]}

Blasio, Angelo ^{[1
]}

Steardo, Antonio ^{[1
]}

Esposito, Giuseppe ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Dept Physiol & Pharmacol V Erspamer, I-00185 Rome, Italy

[2] Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy

来源：

PHYTOTHERAPY RESEARCH | 2009年 / 23卷 / 05期

关键词：

cannabidiol; Cannabis sativa; CNS disorder; phytocannabinoid; IN-VIVO; ANTICONVULSANT ACTIVITY; URINARY METABOLITES; TOXICITY; CANNABINOIDS; SATIVA; MICE; RAT; EXPRESSION; RECEPTORS;

D O I：

10.1002/ptr.2625

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Cannabidiol (CBD) is the main non-psychotropic component of the glandular hairs of Cannabis saliva. It displays a plethora of actions including anticonvulsive, sedative, hypnotic, antipsychotic, antiinflammatory and neuroprotective properties. However, it is well established that CBD produces its biological effects without exerting significant intrinsic activity upon cannabinoid receptors. For this reason, CBD lacks the unwanted psychotropic effects characteristic of marijuana derivatives, so representing one of the bioactive constituents of Cannabis saliva with the highest potential for therapeutic use. The present review reports the pharmacological profile of CBD and summarizes results from preclinical and clinical studies utilizing CBD, alone or in combination with other phytocannabinoids, for the treatment of a number of CNS disorders. Copyright (C) 2008 John Wiley & Sons, Ltd.

引用

页码：597 / 602

页数：6

共 66 条

[1]

[Anonymous], 2003, Drugs R D, V4, P306

[2] Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide [J].

Bisogno, T ;

Hanus, L ;

De Petrocellis, L ;

Tchilibon, S ;

Ponde, DE ;

Brandi, I ;

Moriello, AS ;

Davis, JB ;

Mechoulam, R ;

Di Marzo, V .

BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (04) :845-852

[3] CHARACTERIZATION OF CANNABIDIOL-MEDIATED CYTOCHROME-P450 INACTIVATION [J].

BORNHEIM, LM ;

EVERHART, ET ;

LI, JM ;

CORREIA, MA .

BIOCHEMICAL PHARMACOLOGY, 1993, 45 (06) :1323-1331

[4] Novel cannabinoid receptors [J].

Brown, A. J. .

BRITISH JOURNAL OF PHARMACOLOGY, 2007, 152 (05) :567-575

[5]

CAMPOS AC, 2008, PSYCHOPHARMACOL 0501

[6] CANNABIDIOL AND CANNABIS-SATIVA EXTRACT PROTECT MICE AND RATS AGAINST CONVULSIVE AGENTS [J].

CARLINI, EA ;

LEITE, JR ;

TANNHAUS.M ;

BERARDI, AC .

JOURNAL OF PHARMACY AND PHARMACOLOGY, 1973, 25 (08) :664-665

[7] HYPNOTIC AND ANTI-EPILEPTIC EFFECTS OF CANNABIDIOL [J].

CARLINI, EA ;

CUNHA, JM .

JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 21 (8-9) :S417-S427

[8] Cannabis for dyskinesia in Parkinson disease - A randomized double-blind crossover study [J].

Carroll, CB ;

Bain, PG ;

Teare, L ;

Liu, X ;

Joint, C ;

Wroath, C ;

Parkin, SG ;

Fox, P ;

Wright, D ;

Hobart, J ;

Zajicek, JP .

NEUROLOGY, 2004, 63 (07) :1245-1250

[9] CONTROLLED CLINICAL-TRIAL OF CANNABIDIOL IN HUNTINGTONS-DISEASE [J].

CONSROE, P ;

LAGUNA, J ;

ALLENDER, J ;

SNIDER, S ;

STERN, L ;

SANDYK, R ;

KENNEDY, K ;

SCHRAM, K .

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1991, 40 (03) :701-708

[10] ASSAY OF PLASMA CANNABIDIOL BY CAPILLARY GAS-CHROMATOGRAPHY ION TRAP MASS-SPECTROSCOPY FOLLOWING HIGH-DOSE REPEATED DAILY ORAL-ADMINISTRATION IN HUMANS [J].

CONSROE, P ;

KENNEDY, K ;

SCHRAM, K .

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1991, 40 (03) :517-522

← 1 2 3 4 5 6 7 →